Rossari Biotech Q2 Results FY27: PAT Jumps 5.5% to Rs 38.91 Cr, Revenue Rs 697.56 Cr
- October 17, 2026
- Posted by: Harsh Piplani
- Category: Results
Quick Answer
Rossari Biotech Q2 Results FY27 were declared on 17 October 2026 as consolidated quarterly results for the July to September 2026 quarter. Revenue came in at Rs 697.56 Cr, up 19.02% YoY growth, while net profit stood at Rs 38.91 Cr, up 5.5% YoY growth. The results were announced on a Consolidated basis and the figures also included Operating Profit of Rs 86.97 Cr.
Rossari Biotech Ltd (ROSSARI) Q2 Results FY27 announced on 17 October 2026, covering the company’s financial performance for the July to September 2026 quarter. Rossari Biotech Q2 Results FY27 showed consolidated results with revenue of Rs 697.56 Cr versus Rs 586.11 Cr a year earlier, while net profit rose to Rs 38.91 Cr from Rs 36.88 Cr. The results date is 17 October 2026 and the results-basis phrase is Consolidated.
This review covers the financial highlights, business drivers, outlook and risks, with the discussion moving next to the Financial Highlights section for a clear read-through of the quarter.
Click Here – Get Free Investment Predictions
Rossari Biotech Q2 Results FY27: Financial Highlights
| Metric | Q2 FY27 (Sep 26) | Q2 FY26 (Sep 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 697.56 Cr | Rs 586.11 Cr | +19.02% YoY |
| Operating Profit | Rs 86.97 Cr | Rs 71.92 Cr | +20.93% YoY |
| Net Profit (PAT) | Rs 38.91 Cr | Rs 36.88 Cr | +5.5% YoY |
Source: company filing for Rossari Biotech Q2 Results FY27, 17 October 2026. Figures in Rs Crore, Consolidated basis.
Key Takeaways from Rossari Biotech Q2 Results: What Stands Out
- Revenue: Rs 697.56 Cr, up 19.02% YoY, giving Rossari Biotech Q2 Results FY27 a clear top-line expansion versus last year.
- Net profit: Rs 38.91 Cr, up 5.5% YoY, which shows positive net profit movement in the quarter.
- Operating Profit: Rs 86.97 Cr, up 20.93% YoY, indicating stronger operating profitability than revenue growth alone.
- Results date: The board meeting on 17 October 2026 placed these Rossari Biotech Q2 Results in the current earnings cycle.
- Watchlist: The next read-through for investors is how Rossari Biotech Q2 Results align with later quarterly results and the disclosed risks.
Rossari Biotech Q2 Results FY27: Performance Analysis
Rossari Biotech Q2 Results FY27 show a quarter of higher revenue, better Operating Profit and modest net profit growth. The company reported Consolidated revenue of Rs 697.56 Cr and net profit of Rs 38.91 Cr, so the results analysis points to improvement across the core reported lines without adding any unreported driver.
For the revenue trajectory, the increase to Rs 697.56 Cr from Rs 586.11 Cr reflects 19.02% YoY growth in quarterly results. Operating Profit rose to Rs 86.97 Cr from Rs 71.92 Cr, a 20.93% increase, while net profit increased more slowly at 5.5% YoY. Rossari Biotech Q2 Results therefore show a gap between operating performance and bottom-line growth.
For investors following Rossari Biotech Q2 Results, the next focus is whether future quarterly results keep revenue growth and net profit moving in the same direction. The results analysis now turns to the disclosed business factors, which are the only company-specific reasons available in the filing and help frame the quarter more carefully.
Check the Univest Screener for live results data
Key Business Factors This Quarter
Revenue growth – Revenue grew 19.0% year on year to Rs 697.56 Cr in the latest quarter. This factor directly shaped Rossari Biotech Q2 Results and explains why the top line was the clearest positive in the quarterly results.
Net profit progression – Net profit rose 5.5% year on year to Rs 38.91 Cr. That keeps the bottom line positive in Rossari Biotech Q2 Results, even though the pace was slower than the revenue move.
This longer-term context does not explain the quarter by itself, but it frames the quarterly results within a broader earnings trend.
FY27 Outlook After Rossari Biotech Q2 Results
Rossari Biotech Q2 Results do not include explicit management guidance, so the FY27 outlook has to be read from the reported numbers and the disclosed business context. The results analysis suggests that future net profit and revenue performance will depend on how the next quarterly results develop from this Consolidated base.
For FY27, investors should track whether the current revenue momentum and the reported net profit trend continue in later quarters. Rossari Biotech Q2 Results also need to be viewed alongside sector conditions and subsequent quarterly results, since the filing itself does not provide a forward estimate or directional commentary.
Key Risks to Watch After Rossari Biotech Q2 Results FY27
Return on capital employed
Return on capital employed declined to 14.84% in FY26 from 16.07% in FY25. That historical shift matters when assessing Rossari Biotech Q2 Results, because YoY growth in revenue and net profit still needs to be read against capital efficiency.
Return on equity
Return on equity of 11.88% in FY26 is below 15%. For investors tracking Rossari Biotech Q2 Results, this is a useful risk marker alongside the quarterly results and the reported net profit profile.
Debt position
Debt was 0.31 times total assets in FY26. Rossari Biotech Q2 Results therefore sit within a balance-sheet context that investors may continue to monitor as future YoY growth and quarterly results are disclosed.
Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.
Conclusion
Rossari Biotech Q2 Results FY27 delivered Consolidated quarterly results with higher revenue, stronger Operating Profit and moderate net profit growth. The numbers give a factual read on the results-basis phrase and show what changed in the quarter, while investors should use the reported figures and consult a SEBI-registered advisor before acting on any decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions on Rossari Biotech Q2 Results FY27
What are Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 are the company’s Consolidated quarterly results for the July to September 2026 quarter, showing revenue of Rs 697.56 Cr and net profit of Rs 38.91 Cr.
What is the results date for Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 were announced on 17 October 2026, covering the quarter ended September 2026. The opening paragraphs and the Dividend Details section, where relevant, both anchor the results date.
What revenue was reported in Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 reported revenue of Rs 697.56 Cr, up 19.02% YoY from Rs 586.11 Cr. That figure is shown in the Financial Highlights table and discussed again in Performance Analysis.
What net profit was reported in Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 reported net profit of Rs 38.91 Cr, compared with Rs 36.88 Cr a year earlier. The Key Takeaways section and the Financial Highlights table both place that net profit in context.
How much YoY growth did revenue show in Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 showed 19.02% YoY growth in revenue, taking it to Rs 697.56 Cr. The Performance Analysis section explains that this was a stronger rise than net profit growth.
Did net profit rise or fall in Rossari Biotech Q2 Results?
Ans. Rossari Biotech Q2 Results showed net profit rising to Rs 38.91 Cr, which was 5.5% higher than the same quarter last year. The Key Takeaways section notes that the increase was positive but slower than revenue growth.
What was the Operating Profit in Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 reported Operating Profit of Rs 86.97 Cr, up 20.93% YoY from Rs 71.92 Cr. The Performance Analysis section uses that line to show how operating performance moved.
Are Rossari Biotech Q2 Results FY27 consolidated results or standalone results?
Ans. Rossari Biotech Q2 Results FY27 are Consolidated results for the reported quarter. The Quick Answer box and the opening paragraphs both state the results basis clearly.
What business factors shaped Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 were shaped by revenue growth to Rs 697.56 Cr and net profit rising to Rs 38.91 Cr. The Key Business Factors section also places those figures beside the longer-term earnings context.
What are the key risks after Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 sit against risks including lower return on capital employed and return on equity in FY26. The Key Risks to Watch section also highlights the balance-sheet position as another watchpoint.
What is the outlook after Rossari Biotech Q2 Results FY27?
Ans. Rossari Biotech Q2 Results FY27 do not include explicit guidance, so the outlook depends on subsequent quarterly results and disclosed sector conditions. The FY27 Outlook section explains how investors should frame the next few quarters.
Where can I find the complete Rossari Biotech Q2 Results FY27 data?
Ans. Rossari Biotech Q2 Results FY27 are covered in the Financial Highlights, Performance Analysis and Key Risks sections of this article. Those sections together consolidate the reported revenue, net profit and Operating Profit figures.
